The company has a market capitalization of 874. Please note all regulatory considerations regarding the presentation of fees must be taken into account. has a 52-week low of 14.89 and a 52-week high of 43.26. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Actual performance may differ significantly from backtested performance. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process.
Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Backtested performance is developed with the benefit of hindsight and has inherent limitations. This information is provided for illustrative purposes only. No representations and warranties are made as to the reasonableness of the assumptions. Certain assumptions have been made for modeling purposes and are unlikely to be realized. Changes in these assumptions may have a material impact on the backtested returns presented. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. (NASDAQ:RAPT) by 117.2 in the 3rd quarter, according to its most recent disclosure with the Securities and.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. SG Americas Securities LLC lifted its stake in shares of RAPT Therapeutics, Inc. Backtested performance is not an indicator of future actual results. The Company is also pursuing a range of targets that are in the discovery stage of development.RAPT stock news | RAPT Therapeutics latest news - TipRanksĭisclaimer: The TipRanks Smart Score performance is based on backtested results. RAPT has discovered and advanced two unique drug candidates, RPT193 and FLX475, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of inflammation and cancer, respectively.
#Rapt news drivers#
Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. To access the live webcast or subsequent archived recording of the company presentation, please visit the RAPT Therapeutics website at. Morgan Healthcare Conference on Tuesday, Januat 9:00 a.m. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that Brian Wong, M.D., Ph.D., President and CEO, will present at the 40th Annual J.P. 04, 2022 (GLOBE NEWSWIRE) - RAPT Therapeutics, Inc.
0 kommentar(er)
